Jill Rosenthal's Colleagues at NewAmsterdam Pharma
Jill Rosenthal's Contact Details
N/A
Miami-Fort Lauderdale Area
NewAmsterdam Pharma
Jill Rosenthal's Company Details
Founded in 2019, NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (TA-8995), a novel, selective, cholesteryl ester transfer protein (CETP) inhibitor. The Company is investigating Obicetrapib as the preferred LDL-c lowering therapy for patients who cannot be treated optimally with current available lipid-lowering therapy or for patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally tolerated statin therapy. In January 2021, NewAmsterdam completed its Series A funding round of $196M (€160M) which will support the full Phase 3 development of Obicetrapib.